SPRY - ARS Pharmaceuticals, Inc.
IEX Last Trade
11.1
0.020 0.180%
Share volume: 37,468
Last Updated: Thu 26 Dec 2024 08:30:19 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$11.08
0.02
0.18%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-02 | 2023-03-23 | 2023-05-15 | 2023-08-10 | 2023-11-09 | 2024-03-21 | 2024-05-09 | |
| Total revenue | 0.000 | 0.000 | 1.316 M | 20.000 K | 10.000 K | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 1.316 M | 20.000 K | 10.000 K | 0.000 | 0.000 | 0.000 | |
| nan% | inf% | -98.48% | -50.00% | -100.00% | nan% | nan% | |||
| Operating expenses | 19.798 M | 18.619 M | -26.283 M | 18.733 M | 20.613 M | 17.978 M | 10.226 M | 13.192 M | |
| Selling general and admin | 7.553 M | 10.256 M | -7.154 M | 12.181 M | 13.305 M | 14.976 M | 6.822 M | 7.958 M | |
| Research and development | 12.245 M | 8.363 M | -19.129 M | 6.552 M | 7.308 M | 3.002 M | 3.404 M | 5.234 M | |
| Total expenses | 19.798 M | 18.619 M | -26.283 M | 18.733 M | 20.613 M | 17.978 M | 10.226 M | 13.192 M | |
| -5.96% | -241.16% | 171.27% | 10.04% | -12.78% | -43.12% | 29.00% | |||
| Operating income | -19.798 M | -18.619 M | 27.599 M | -18.713 M | -20.603 M | -17.978 M | -10.226 M | -13.192 M | |
| Ebit | -19.798 M | -18.619 M | 27.599 M | -18.713 M | -20.603 M | -17.978 M | -10.226 M | -13.192 M | |
| Pretax income | -19.429 M | -17.864 M | 27.242 M | -14.961 M | -17.370 M | -14.866 M | -7.168 M | -10.292 M | |
| -8.05% | -252.50% | -154.92% | 16.10% | -14.42% | -51.78% | 43.58% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -19.429 M | -17.864 M | 27.242 M | -14.961 M | -17.370 M | -14.866 M | -7.168 M | -10.292 M | |
| 8.05% | 252.50% | -154.92% | -16.10% | 14.42% | 51.78% | -43.58% | |||
| Net income | -19.429 M | -17.864 M | 27.242 M | -14.961 M | -17.370 M | -14.866 M | -7.168 M | -10.292 M | |
| 8.05% | 252.50% | -154.92% | -16.10% | 14.42% | 51.78% | -43.58% |